New drug duo takes on tough bile duct cancer in head-to-head trial
NCT ID NCT07152769
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 24 times
Summary
This study tests whether a new combination of immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy works better than another immunotherapy plus chemotherapy for people with advanced intrahepatic cholangiocarcinoma, a type of bile duct cancer. About 104 adults will be randomly assigned to one of the two treatment groups. The main goal is to see how many patients stay cancer-free or alive after 6 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED INTRAHEPATIC CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200062, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.